Apr 22, 2019
CORMEDIX ANNOUNCES ONLINE PRE-CLINICAL ABSTRACT AT THE UPCOMING ANNUAL MEETING OF AMERICAN SOCIETY OF CLINICAL ONCOLOGY
Apr 17, 2019
CORMEDIX COMPLETES SALE OF $5.4 MILLION OF NOL TAX BENEFITS THROUGH NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY PROGRAM
Apr 11, 2019
CORMEDIX NOTIFIED OF COMPLIANCE WITH NYSE AMERICAN LISTING REQUIREMENTS
Mar 25, 2019
CORMEDIX CONFIRMS PREVIOUSLY ANNOUNCED ONE-FOR-FIVE REVERSE STOCK SPLIT
Mar 21, 2019
CORMEDIX INC. ANNOUNCES APPOINTMENT OF PHOEBE MOUNTS AS EXECUTIVE VICE PRESIDENT AND GENERAL COUNSEL
Mar 14, 2019
CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS, ANNOUNCES REVERSE STOCK SPLIT AND PROVIDES BUSINESS UPDATE
Mar 4, 2019
CORMEDIX INC. APPOINTS ALAN W. DUNTON, M.D. TO BOARD OF DIRECTORS
Feb 14, 2019
CORMEDIX INC. ANNOUNCES FDA MEETING UPDATE
Jan 30, 2019
CORMEDIX INC. ANNOUNCES TOPLINE ANALYSIS OF THE FULL DATA SET OF PHASE 3 LOCK-IT-100 STUDY REINFORCES THE INTERIM RESULTS
Jan 17, 2019
CORMEDIX INC. ANNOUNCES HIGHLY STATISTICALLY SIGNIFICANT TOPLINE RESULTS FOR NEUTROLIN® FROM THE INTERIM ANALYSIS OF THE PHASE 3 LOCK-IT-100 STUDY
Jan 17, 2019
CORMEDIX INC. ANNOUNCES RESIGNATION OF MEMBER OF ITS BOARD OF DIRECTORS
Jan 7, 2019
CORMEDIX ANNOUNCES CLOSING OF $7.5 MILLION SENIOR SECURED CONVERTIBLE DEBT FINANCING
Dec 10, 2018
CORMEDIX RECEIVES APPROVAL TO SELL $5.4 MILLION OF NOL TAX BENEFITS THROUGH THE NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY PROGRAM
Nov 14, 2018
CORMEDIX INC. REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call today at 4:30 p.m. Eastern Time
Oct 18, 2018
CORMEDIX INC. CLARIFIES THAT NO NEW SHARES ARE BEING ISSUED IN CONNECTION WITH ITS RECENTLY FILED FORM S-3 REGISTRATION STATEMENT
Aug 31, 2018
CorMedix Announces NYSE American Acceptance of Plan to Regain Listing Compliance
Aug 30, 2018
CORMEDIX INC. TO PRESENT AT THE 20TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE
Aug 14, 2018
CORMEDIX INC. REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Jul 25, 2018
CORMEDIX INC. ANNOUNCES POSITIVE RESULTS OF ITS NEUTROLIN® PHASE 3 LOCK-IT-100 STUDY BASED ON RECOMMENDATION BY INDEPENDENT DATA SAFETY MONITORING BOARD
Jun 20, 2018
CORMEDIX INC. COMPLETES REVIEW AND SOURCE VERIFICATION OF PHASE 3 LOCK-IT 100 DATA FOR NEUTROLIN®
